Heart failure is a chronic condition in which the heart cannot pump enough blood to meet the body’s needs. It often develops after damage from a heart attack, longstanding high blood pressure, or cardiomyopathies that weaken or stiffen the heart muscle. Researchers distinguish between heart failure with reduced ejection fraction, where the heart’s pumping ability is weakened, and heart failure with preserved ejection fraction, where the heart becomes stiff and cannot fill properly.

Current research emphasizes early detection and risk prediction. Large cohort studies and registries are identifying clinical and biochemical markers that help predict who will develop heart failure and who is at highest risk of hospitalization or death. Biomarkers such as natriuretic peptides, along with imaging measures of cardiac structure and function, are central to this work.

Therapeutic research has expanded beyond traditional drugs like ACE inhibitors, beta blockers and mineralocorticoid receptor antagonists. Newer drug classes, in particular SGLT2 inhibitors originally developed for diabetes, have shown consistent benefits in reducing hospitalizations and cardiovascular deaths across different heart failure phenotypes. Other studies are testing drugs that target fibrosis, inflammation, and metabolic dysfunction in the myocardium.

There is also active investigation into non drug strategies. These include device therapies to improve electrical coordination of the heart, mechanical support systems for advanced cases, and digital tools such as telemonitoring to detect clinical deterioration early. Lifestyle and rehabilitation programs remain important, with research focusing on optimizing exercise prescriptions and dietary strategies. Overall, recent findings are reshaping both prognosis and day to day management for people living with heart failure.